Abstract. Heparan sulfate proteoglycans (HSPGs) are found on the surface of all adherent cells and participate in the binding of growth factors, extraceUular matrix glycoproteins, cell adhesion molecules, and proteases and antiproteases. We report here the cloning and pattern of expression of cerebroglycan, a glycosylphosphatidylinositol (GPI)-anchored HSPG that is found in the developing rat brain (previously referred to as HSPG M13; Herndon, M. E., and A. D. Lander. 1990 . Neuron. 4:949-961), The cerebroglycan core protein has a predicted molecular mass of 58.6 kD and five potential heparan sulfate attachment sites. Together with glypican (David, G., V. Lodes, B. Decock, P. Marynen, J.-J. Cassiman, and H. Van den Berghe. 1990. J. Cell Biol. 111:3165-3176), it defines a family of integral membrane HSPGs characterized by GPI linkage and conserved structural motifs, including a pattern of 14 cysteine residues that is absolutely conserved. Unlike other known integral membrane HSPGs, including glypican and members of the syndecan family of transmembrane proteoglycans, cerebroglycan is expressed in only one tissue: the nervous system. In situ hybridization experiments at several developmental stages strongly suggest that cerebroglycan message is widely and transiently expressed by immature neurons, appearing around the time of final mitosis and disappearing after cell migration and axon outgrowth have been completed. These results suggest that cerebroglycan may fulfill a function related to the motile behaviors of developing neurons. p ROTEOGLYCANS (PGs)~-proteins that bear glycosaminoglycan (GAG) side chains-are abundant surface components of all adherent cells, and are thought to play important roles in cell growth, morphogenesis and cancer (7, 23, 57) . Most commonly, cell-surface PGs bear GAG chains of the heparan sulfate (HS) class and, because of this, have the potential to interact with many extracellular heparin-binding proteins, including extracellular matrix molecules, cell-cell adhesion molecules, cell-surface enzymes, and growth factors (35, 43) . It has been proposed that cell-surface HSPGs act as "co-receptors" for such proteins, functioning to bring them together with more conventional molecules (e.g., signal-transducing receptors) on the cell surface (7). Strong evidence for this model comes from studies of the interaction of basic fibroblast growth factor with one of its tyrosine kinase receptors, an interaction that
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The co-receptor model provides a useful framework within which to understand the general functions of HSPGs, but leaves open the question of whether specific functions are associated with individual molecular species of HSPG. Currently, five distinct polypeptides are known to be major carriers of HS on mammalian cells. Four of these are transmembrane proteins, and form a gene family, the syndecans, on the basis of strong evolutionary conservation in their cytoplasmic and transmembrane domains (7) . The fifth is a glycosylphosphatidylinositol (GPI)-anchored protein known as glypican (19) . The expression of these PG core proteins varies dramatically from tissue to tissue, especially during the course of development (7) . Tissue-specific and developmental variation also occurs in the structure of the HS that is found on these core proteins, and such variation can give rise to substantial differences in the binding properties of intact PGs (49, 51, 58, 62, 63) . Taken together, the data sug-gest that individual HSPGs may indeed be specialized to carry out particular functions.
To explore this possibility, we have chosen to focus on the developing mammalian nervous system, a tissue in which heparin-binding molecules mediate numerous cell-cell, cell-matrix, and cell-growth factor interactions (42) , and in which developmental processes occur with precise timing and anatomical localization. Previously, we demonstrated that '~25 PG core proteins can be detected in the developing and adult rat brain (30) . Of these, three species exhibited detergent partitioning properties indicative of integral membrane proteins. These three molecules, all of which are HSPGs, are thus likely to represent the major cell surface PGs of the central nervous system. One of these ("M7; ref. 30 ) is indistinguishable in biochemical properties and timing of expression from a member of the syndecan family, N-syndecan, or syndecan III, which is expressed in perinatal brain, peripheral glia, developing limbs, and other tissues (11, 28) . The second ("M12") is the GPI-anchored HSPG glypican (46) . The third species ("M13") is also a GPIanchored HSPG, and could be isolated from the developing brain, but not from adult (30) .
We report here on studies that identify the M13 core as a novel membrane protein. We confirm that it is expressed only during development and demonstrate that, unlike other PGs, M13 is restricted in expression to a single tissue-the nervous system. Moreover, although this PG is widely expressed in many regions of the developing nervous system, the data suggest that expression is associated with neurons and is closely linked, in each region, to the time period when postmitotic neurons undergo migration and axon outgrowth, their major morphogenetic movements. The deduced amino acid sequence of this PG, which we call cerebroglycan, indicates that it, together with glypican, defines a new family of cell-surface HSPGs, the GPI-anchored PGs. Interestingly, the core proteins in this family exhibit an unexpectedly high degree of structural homology, raising the possibility that these molecules have evolved for more specialized functions than simply to be the passive bearers of GAG chains.
Materials and Methods

Materials
Heparitinase was purified from Flavobacterium heparinum by hydroxyapatite and phosphocellulose chromatography (45) . The GAPDH eDNA clone was the generous gift of Dr. Timothy Hayes (National Institutes of Health [NIH], Bethesda, MD). All restriction enzymes were from New England Biolabs (Beverly, MA). Chondroitinase ABC, Triton X-100, NEM (N-ethylmaleimide), pepstatin A, and PMSF, Hoechst 33258 dye (bisbenzimide), and PVP-40 (polyvinyl pyrrolidone) were obtained from Sigma Chemical Co. (St. Louis, MO). Trypsin, RNAse A, CHAPS (3-[(3 Cholamidopropyl) dimethyl-ammonio]-l-propanesulfonate), and yeast RNA were from Boehringer Mannheim Corp. (Indianapolis, IN). RNA and DNA ladders were from GIBCO BRL (Gaithersburg, MD). Nitrocellulose was from Schleicher and SchueU (Keene, NH). DEAE-Sephacel, dextran sulfate, salmon sperm DNA, and ~ DNA polymerase were from Pharmacia Fine Chemicals (Piscataway, NJ). Fornmmide was from Fluka (Buchs, Switzerland). ~2p_ labeled dCTP and a35S-iabeled UTP were from DuPont NEN (Boston, MA). All other reagents were from Mallinckrodt (Paris, KY), except as noted.
Purification and Microsequencing of HSPG M13
Detergent extracts of a crude membrane fraction of neonatal (P0) SpragueDawley rat brains were prepared (30) and stored at -800C. Extracts from a total of 46.4 g (wet weight) of brain were used to purify PGs by anion exchange chromatography on DEAE-Sephacel (30) . At this point, 0.3/zCi of t25I-labeled, membrane-associated PGs, purified and radiolabeled as previously described (30) , was added to the PG pool as a tracer.
Centriprep-10 tubes (Amicon Corp., Beverly, MA) were used to concentrate the eluate and exchange the elution buffer for 50 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% Triton X-100. The sample was then treated with Chondroitinase ABC (0.09 U/ml) in the presence of 1 mM EDTA, 1/~g/ml pepstatin, and 0.4 mM PMSF for 2 h at 37°C, and loaded immediately onto a DEAE-Sephacel column (0.2 ml packed volume), equilibrated in 50 mM Tris-HCl, pH 8.0, 0.15 M NaCI, 0.1% Triton X-100. The column was washed successively with 0.2 M NaC1, 100 mM sodium acetate, pH 3.5, 0.1% Triton X-100; 0.1 M Tris-HCl, pH 8.0, 0.1% Triton X-100; 50 mM Tris-HC1, pH 8.0, 0.1% Triton X-100; and 25 mM ammonium acetate, pH 7.0, 0.1% Triton X-100. An HSPG-enriched fraction was eluted with a 20-ml gradient of NaC1 from 0.15 to 0.75 M, in 25 mM ammonium acetate, pH 7.0, and 0.1% Triton X-100. All radioactive fractions eluted by ~,0.3 M NaCI were pooled. In this manner, approximately 80 ~tg of HSPG were recovered (as determined by amino acid analysis).
A Centricon-10 (Amicon Corp.) tube was used to concentrate the pooled sample and exchange the buffer to 50 mM NaC1, 25 mM ammonium acetate, 0.1% Triton X-100. The sample was made 25 mM in Tris-HC1 (pH 7.1 at 37"C), and protease inhibitors added along with heparitinase to a final concentration of 9 tzg/ml. The HSPG sample was digested for 3 h at 37°C, concentrated in a Centricon-10 tube and loaded to a 9% SDS-PAGE gel. A control digest of identical composition but with no HSPGs was loaded in an adjacent lane of the gel. After electrophoresis, the gel was electroblotted overnight at 25 V and 4°C to nitrocellulose in 25 mM Tris-HCl, pH 8.3, 20 % (vol/vol) ethanol, 0.005 % SDS. Bands were visualized by staining with Amido Black (64) , and the band corresponding to HSPG MI3 was excised, as was a corresponding region from the control lane.
The nitrocellulose-bound HSPG M13 was blocked with PVP-40 (0.5% in 100 mM acetic acid at 37"C for 30 rain) and then digested with trypsin for 18 h at 37°C in 100 mM ammonium carbonate/acetonitrile (95:5 by volume) (68) . Released digestion products were analyzed by reverse phase HPLC on a Hewlett Packard model 1090L HPLC equipped with a "~jdac 21gl'P52 C18 column (Vydac, Hesperia, CA), and multiple peaks of absorbance at 210 um were collected and subjected to microsequencing by automated Edman degradation.
PCR Amplification of an HSPG-M13 cDNA
Degenerate PCR primers were designed based on the sequence of poptide M13-22 (see Results and Table I ). The sequences of the primers were 22L: 
Library Construction and Screening
P0 rat brain polyA-enriched RNA was prepared by fractionation on oligo dT cellulose using a Fast Track mRNA isolation kit (Invitrogen, San Diego, CA). cDNA was synthesized from 5 t~g of poly(A) + RNA using an oligo dT primer with the ZAP eDNA synthesis kit (Stratagene, La JoUa, CA). The resulting eDNA was ligated into EcoRI-XhoI digested and dephosphorylated Uni-ZAP XR vector arms (Stratagene) and packaged for plating (Giga Pack Gold II; Stratagene). The library was amplified once before plating on XL1-Blue host cells. The library was screened with a probe generated by a PCR reaction (as described above), which included ot32P-dATE A primer-extended library was synthesized from 5/~g of polyA~entiched RNA (prepared as described above) and 120 pmol of primer M13A-165 (based on the sequence of eDNA MI3-A, see Results) using a Timesaver eDNA synthesis kit (Pharmacia Fine Chemicals). The resulting eDNA, ligatnd to EcoRl adaptors, was cloned into EcoRI-digested, depbosphorylated )~-gtl0 arms (Stratagene), packaged (Giga Pack Gold II; Stratagene), and plated on NM514 host cells for screening with a probe generated from the 100 bp BgllI fragmem of M13-A (see Results) by random-primer labeling (70200 Random Primed DNA Labeling Kit; United States Biochemical Corp., Cleveland, OH). or pSL301 (Invitrogen). eDNA inserts were sequenced by the dideoxy chain termination method using a modified T7 DNA polymerase (Sequenase kit 2.0; United States Biochemical Corp.). T3, T7, and M13 (-40) primers, as well as custom made primers, were used in reactions with denatured, supercoiled plasmids. All sequences were determined with both dGTP and dlTP. 
Southern Blot Analysis
Rat genomic DNA was prepared from Sprague-Dawley rat thymocytes ac-M 13-10 cording to Sambrook et al. (60) , and stored at 4"C under ethanol. 20 t~g of DNA, digested to completion with HindIII, KpnI, or XhoI, was electrophoresed and blotted to nitrocellulose according to Sambrook et al. (60) . Prehybridization, hybridization, and washing, were done according to M13-21 Church and Gilbert (14) . The filter was autoradiographed with XAR-5 film (Eastman Kodak Co., Rochester, NY).
Northern Blot Analysis
Total RNA was isolated by guanidinium isothiocyanate extraction (13) . 20 #g of total RNA from embryonic day 18 (El8), P0, and adult rat brain was used for the Northern analysis, performed according to Sambrook et al. (60) , except that yeast RNA (200/zg/ml) and salmon sperm DNA (100 /~g/ml) were included in the hybridization buffer. Filters were exposed to Kodak XAR-5 film or imaged with a phosphorimager (Molecular Dynamics, Inc., Sunnyvale, CA). The blot was re-probed for glyceraldehydephosphate dehydrogenase (GAPDH) mRNA to normalize for different loading and transfer etliciences between the lanes.
In Situ Hybridization
Freshly dissected rat embryos were quick-frozen in isopentane on dry ice and stored at -80°C. Before sectioning, samples were equilibrated to -200C and embedded in OCT medium. 12-20-/zm cryostat sections were collected on gelatin-subbed slides or on Probe-On Plus slides (Fisher Biotech; Pittsburgh, PA) and stored at -80°C with desiccant. Sections were equilibrated to room temperature, fixed in 4% paraformaldehyde in PBS at room temperature for 5 min, and washed twice in 2 x SSC. Prehybridization treatments, hybridization, and post-hybridization washes were performed according to Simmons et al. (67) , except that the proteinase K step was omitted. After hybridization, sections were exposed to hyperfilm/~max (Amersham Corp., Arlington Heights, IL) for 5-7 d at -800C. Selected sections were dipped in Kodak NTB-2 liquid emulsion that had been diluted 1:1 in ddH20, and exposed for 12-21 days at -80°C. Developed sections were stained in Hoechst 33258 (bisbenzimide) at 1 /~g/ml in ddH20 or cresyl violet (0.5 % in ddH20), and examined by fluorescence, bright field, and dark field illumination on a Zeiss Axiophot microscope, or a Nikon Diaphot microscope.
Results
Molecular Cloning of HSPG MI3
To establish the molecular identity of the M13 core protein, a PG-enriched fraction was prepared by DEAE-chromatography of a detergent extract of neonatal rat brain membranes (30) . The PG fraction was depleted of chondroitin sulfate PGs by treatment with chondroitinase ABC and refractionation on DEAE-Sephacel. After heparitinase digestion, separation by SDS-PAGE, and electroblotting to nitrocellulose, Amido Black staining revealed two major species. On the basis of the previously characterized molecular weights of neonatal rat brain membrane HSPG cores (30) one species was identified as HSPG M13, and the other as M12. Both bands were excised from the membrane and separately digested in situ with trypsin. The peptides released were separated by HPLC chromatography and selected peaks chosen for amino acid sequencing.
The data obtained from HSPG M12 indicated that this molecule is the rat homologue of glypican (46) . In contrast, the four M13-derived peptides that were obtained (Table I) did not closely match any sequences in the NBRF database,
Selected M 13 tryptic peptides were subjected to automated Edman degradation after separation by reverse-phase HPLC. Multiple letters indicate ambiguities in the sequence, bold letters indicate the sequence which was later verified from the deduced amino acid sequence of M13 eDNA. 22L and 22R: bars indicate the unambiguous amino acid sequence upon which the PCR primers 22L and 22R were based.
but could be aligned with human glypican so as to reveal an overall sequence identity of 58 %. These data suggested that M13 might be a glypican-related molecule.
To facilitate further characterization of HSPG M13, a eDNA was obtained from neonatal rat brain by PCR. Using primers 22L and 22R, which were based on unambiguous sequence at either end of peptide M13-22 (Table I) , a major PCR product of ~80 bp was obtained. This product was subcloned and two independent clones were isolated and sequenced. Both contained the sequences of primers 22L and 22R, and the intervening sequences of both gave a deduced protein sequence which was an exact match for peptide M13-22 (data not shown), verifying that a genuine M13 eDNA had been amplified.
To obtain a complete eDNA, a neonatal rat brain eDNA library was screened with a probe generated by PCR using ota2P-labeled dATP and primers 22L and 22R, with the gelpurified 80-bp M13 eDNA fragment as the template. Three positive plaques were identified out of 900,000 screened in the amplified library. All three were plaque purified, and all contained inserts of "~1,600 bp. Preliminary sequence data supported the conclusion that all three inserts were identical products of a single cloning event. Additional sequencing of this eDNA, referred to hereafter as M13-A, showed that it contained an 862-bp open reading frame followed by 659 bp of 3' untranslated sequence, and was unlikely to encode full length M13. Therefore, a primer extended library was constructed using neonatal rat brain RNA and a primer based on sequence 165 bp from the 5' end of M13-A. The library was screened with a random-primer labeled probe generated from the 100 bp BglII fragment of M13-A (see Fig. 1 ), and 52 positives were identified out of 9 x 104 plaques. Two of these, M13PX-1 and M13PX-2, were plaque purified and found to contain inserts of ,~1,200 and ~1,100 bp, respectively. The combined length of M13-A and the overlapping M13PX-1 is an excellent match for the size of the M13 mRNA observed in Northern analyses (see below), indicating that together, M13-A and M13PX-1 constitute an es- . 2 ), including the three that were not used in screening the cDNA library. The deduced amino acid sequence features a stretch of hydrophobic amino acids at both the amino and carboxy termini, which could serve as a signal sequence and a GPIattachment signal respectively. HSPG M13 was previously shown to be GPI-linked on the basis of its ability to be released from Triton X-114 micelles by phosphatidylinositol specific-phospholipase C (30). With the removal of these sig- nal sequences, the mature protein would have a predicted molecular mass of 58.6-kD, in good agreement with the size of the M13 core protein, as observed on reducing SDS-PAGE gels (57 kD) (30) . The protein contains seven "ser-gly" sequences, five of which (boxed in Fig. 2 ) are potential GAG attachment sites (see Discussion). No "N-X-S" or "N-X-T" N-linked glycosylation consensus sequences are present. As Fig. 3 illustrates, the M13 protein sequence shows significant homology to two other molecules, rat glypican (37, 46) , and the deduced protein sequence of OCI-5, a developmentally regulated transcript cloned from a primitive intestinal epithelial rat cell line (25) . The homology is moderate but extensive, with islands of highly conserved sequence surrounded by divergent sequences. Most striking is the conservation of cysteine residues (heavy lines in Fig. 3 ): Of the 14 cysteines in the predicted sequence of the mature M13 protein, all are conserved in both glypican and OCI-5. In fact, the only cysteines in mature glypican and OCI-5 that are not found in M13 are a single pair near the COOH terminus. In addition, glypican and M13 share three putative sergly GAG attachment sites (Fig. 3, boxes) , and one of these is present in OCI-5 as well. M13 and glypican are more closely related to each other, with an amino acid identity of 37 %, than either M13 to OCI-5 or glypican to OCI-5, with 20 % and 21% identities, respectively. 20 #g of rat genomic DNA was digested to completion with one of three restriction enzymes, separated by electrophoresis, blotted to nitrocellulose, and probed with an ~32P-dCTP-labeled MI3 probe. The sizes of DNA standards are indicated. The restriction enzymes used were HindlII (H), KpnI (K), and XhoI (X).
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Southern Hybridization
To assess whether M13 is present as a single copy in the genome, 10 #g of rat thymus DNA was digested to completion with HindlII, KpnI, or XhoI, separated by agarose gel electrophoresis, and transferred to nitrocellulose. The filter was probed with a random primer-labeled probe made from the 100-bp BglII fragment of the M13-A eDNA. The resulting autoradiogram is shown in Fig. 4 . In each lane a single band appears indicating that the gene encoding M13 is present as a single copy in the rat genome.
Developmental Expression
M13 is observed in the membrane fraction of embryonic day 18 (El8) and newborn (P0) rat brain, but not in the adult (30) . To assess the expression of M13 mRNA, Northern blot analysis was performed using 20 #g of total RNA from each of these three developmental stages, and a random-primer- 
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labeled probe generated using cDNA M13-A as the template (Fig. 5) . A single transcript of'x, 2.7 kb was seen that is relatively abundant at El8, less so at P0, and undetectable in the adult sample. The filter was re-probed with a glyceraldehydephosphate dehydrogenase (GAPDH) probe (Fig. 5, lower  panel) , demonstrating that there was not an appreciable difference in the amount of RNA loaded in each lane. Thus, the developmental expression of M13 mRNA agrees with that previously observed for M13 protein (30) .
To localize M13 expression in the developing animal, in situ hybridization was performed. The 306 bp SacI or the 223 bp ApaI-KpnI pBluescript subclones of the M13 cDNA, M13-A (Fig. 1) , were used to generate ot3sS-UTP labeled RNA probes. Fig. 6 shows the results obtained when these probes were hybridized to fresh-frozen sections of embryonic day 14 (El4), 16 (El6), and 19 (El9), and newborn (P0) animals. The results are presented as "reverse contrast" images, printed directly from autoradiograms of the sections.
In El4 and El6 animals (Fig. 6 , B and D) strong MI3 expression occurs along the entire neuraxis, including the brain, spinal cord, dorsal root ganglia, and cranial nerve ganglia. No expression in any non-neural tissue could be detected. By El9 (Fig. 6 F) , expression in the spinal cord and dorsal root ganglia is dramatically lower than in the many regions of the brain that still express high levels of M13 message, including the cerebral cortex, hippocarnpus, corpus striaturn, inferior colliculus, and pontine nuclei. As at earlier stages, hybridization to non-neural tissues was not above background. In the P0 head (Fig. 6 I) , strong expression persists in the cerebral cortex, hippocampus, striatum, inferior colliculus, and cerebellar cortex, but only weak expression is seen elsewhere in the brain. Again, expression was not observed outside the nervous system. Fig. 6 G shows an example of the results obtained when the opposite strand control probe was hybridized to a nearly adjacent section (in this case, in the E19 animal). No hybridization above background was observed in any tissue.
AS Fig. 6 illustrates, M13 is globally expressed in the nervous system at early stages. AS neural development proceeds expression is selectively lost from certain structures while remaining in others. A closer examination of the pattern of expression suggested that M13 mRNA remains in structures for several days after neurogenesis-the production of postmitotic neurons-has ended (see Discussion). This raised the possibility that M13 expression might be associated with neuronal precursors and/or immature neurons.
To more accurately examine the relationship between M13 expression and neuronal development, in situ hybridization was carried out using sections of postnatal day 7 (P7) brain. At this age, the generation and early development of neurons has finished in most of the brain, but persists in three latedeveloping areas: the external granule layer of the cerebellum, the dentate gyrus of the hippocampus, and interneurons of the olfactory bulb (34) . As shown in Fig. 7, M13 is expressed at this stage in precisely these three areas: the folia of the cerebellum, the dentate gyrus of the hippoeampus, and the olfactory bulb. As with the earlier experiments, no hybridization with the opposite-strand control probe was detected (not shown).
A higher magnification view of the cerebellum (Fig. 8 A) reveals that M13-expressing cells are found in the external granule layer (EGL), the zone in which granule cells (cerebellar interneurons) are generated and undergo initial stages (~28 h) of development (26) . In contrast, the internal granule layer (IGL), which contains mature granule cells, was essentially devoid of hybridization. A higher magnification view of the olfactory bulb (not shown) revealed that M13-expressing cells are localized to the subventricular zone, the site of postnatal production of olfactory bulb interneurons (granule cells and periglomerular cells) (48) . In contrast, layers containing mature olfactory bulb neurons were devoid of M13 hybridization (these layers lie anterior to the indicated region of hybridization in Fig. 7 , and were visualized by Hoechst 33258 fluorescence) (not shown).
These results suggest that, at least in these tissues, expression of M13 is restricted to an early stage in the development of neurons. An indication of how early M13 appears can be obtained by examining the distribution of cells within the external granule layer of the cerebellum. As shown in Fig. 8 A, M13-expressing cells are strongly concentrated within the deeper half of the external granule layer, the so-called premigratory zone (26) . This zone consists of newly generated, postmitotic neurons, whereas the superficial half of the external granule layer contains the proliferating cells that give rise to those neurons. This result indicates that M13 expression begins in neurons at or about the time they become postmitotic.
To further test this hypothesis, in situ hybridization was used to examine M13 expression in the embryonic day 12 (El2) spinal cord. At this stage, the spinal cord consists of a large central proliferative zone (the ventricular zone), from which newly postmitotic neurons migrate laterally to form the nascent ventral and dorsal horns (3). As Fig. 8 B illustrates, M13 is strongly expressed by regions of the El2 spinal cord that contain postmitotic neurons, but weakly expressed, if at all, by the still-proliferating neural precursors of the ventricular zone. In addition, expression can be seen in the dorsal root ganglia (DRG) located on either side of the spinal cord. These structures also contain recently post-mitotic neurons (3), the progeny, in this case, of neural crest cells.
These data suggest that M13 is specifically and transiently expressed by neurons during their immediate post-mitotic period. As discussed below, the window of expression of this molecule correlates particularly well, throughout the nervous system, with the time period during which neuronal migration and axon outgrowth take place.
Discussion Molecular Cloning of Cerebroglycan
Several lines of evidence confirm that the cDNA obtained in this study encodes the GPI-anchored HSPG core protein previously designated as M13 (30): The cDNA encodes all four of the peptides that were obtained from a tryptic digest of M13; it encodes a protein of the correct size, which contains likely GPI anchorage and GAG-attachment sequences (see below); and it hybridizes to an rnRNA that is present in embryonic and neonatal rat brain, but not in adult brain (matching the pattern previously observed for M13 protein) (30) . In situ hybridization demonstrated that, at every stage so far examined, expression ofHSPG M13 is limited to the nervous system. This result is surprising because no other proteoglycan is known to be restricted in expression to a single tissue. To reflect the nervous system-specific expression of this proteoglycan, we have chosen to name PG M13 "cerebroglyeanY
Sequence Analysis
The deduced amino acid sequence of cerebroglycan contains seven serine-glycine pairs, representing possible GAG attachment sites. Of these, set ~55, ser 49s and ser 5°° all match the sequence SGXG, and all occur within regions of protein sequence that are rich in acidic residues. Both features have been proposed to define a consensus for GAG attachment (7, 8) . In addition, two other serine-glycine pairs (ser 55 and ser 02) occur either just before or just after an acidic residue, and might also represent GAG attachment sites (7) . Interestingly, sel "49s and ser ~ were sequenceable residues of peptide M13-22. Since substitution of serine with GAG chains should result in a blank cycle in Edman degradation, it is possible that these sites are not actually substitu*ed with GAG chains, or that only a fraction of cerebroglycan core proteins are substituted at both these sites.
The cerebroglycan protein sequence has a stretch of hydrophobic amino acids at both the amino and carboxy termini, as indicated in Fig. 2 . These sequences could serve as the signal sequence and a GPI-attachment signal respectively, being cleaved off in the mature protein. The precise cleavage sites are unknown, and those indicated in Fig. 2 are predictions based upon the -1,-3 rule (72), for the signal sequence, and the ~o, w + 2 rule (39), for the GPI-attachment signal. Of the two potential GPI-attachment sites indicated, ser 55~ has a slightly higher probability than ash 55~, based on amino acid preferences at the ~0 and o~ +2 sites of other GPIanchored proteins. After the candidate GPI-attachment sites are a potential "hinge" region (rich in proline and charged amino acids), and a stretch of hydrophobic amino acids; both the hinge and hydrophobic stretch are features of GPI attachment signals (39) .
Cerebroglycan Defines a Family of GPI-Anchored PGs
The deduced amino acid sequence of cerebroglycan shares significant homology with two other molecules, the GPIanchored HSPG glypican, and the predicted product of a developmentally regulated transcript, OCI-5, that was cloned from a rat primitive intestinal epithelial cell line (Fig. 3) . The most striking feature of the homology is the absolute conservation of 14 cysteine residues. It is likely that these residues are involved in stabilizing a highly compact tertiary structure, since both glypican and cerebroglycan exhibit apparent molecular masses on SDS-PAGE gels that are ~10 kD lower under nonreducing conditions than under reducing conditions (30) . A search of protein databases revealed no other molecules with a similar pattern of cysteines in their primary structures. Thus, cerebroglycan, glypican, and OCI-5 apparently constitute a new family of proteins characterized by similar core protein size, GPI linkage, the presence of potential GAG attachment sites, and a unique cysteine pattern. Since the protein encoded by the OCI-5 transcript has yet to be purified, it remains to be seen whether this molecule actually bears GAG chains in vivo.
Of the four major transmembrane HSPGs that have been identified to date, all were recently classified into a single gene family, on the basis of homology with syndecan (7) . The data presented here suggest that the GPI-anchored HSPGs-which are also major PGs in many cells (10, 21, 33, 77) -may also be classifiable into a single gene family. It is interesting that members of the syndecan family exhibit significant sequence similarity only in their transmembrane and cytoplasmic domains, while their extracellular domains have diverged rapidly, even among orthologues in different mammalian species (7). These results have suggested that the extracellular domains of syndecans may serve no conserved function other than as a protein scaffold onto which GAG chains are attached. In contrast, the GPI-anchored HSPG family exhibits a high degree of sequence similarity among homologues, and appears to be evolving more slowly than the syndecans (e.g., rat and human glypican are 91% identical in their mature protein sequences [37, 46] , while the extracellular domains of mouse and human syndecan-1 are only 70% identical [7] ).
This analysis raises the possibility that the cerebroglycan, glypican, and OCI-5 polypeptides subserve functions other than just the anchorage of GAG chains to the cell surface.
For example, these core proteins might bind as yet unknown ligands. Other ligand-binding PG core proteins include the core proteins of betaglycan (which binds TGF-B) (12) and decorin (which binds to collagen fibrils) (41, 71) .
Alternatively, the conserved protein structure of the GPIanchored HSPGs may play a regulatory role in posttranslational processing. For example, the protein might interact with components of the Golgi apparatus in order to influence the type of GAG that it receives (e.g., HS versus chondroitin sulfate), or even the sequence of GAG modifications (e.g., sulfation) that is subsequently generated. Recent studies underscore the importance of differences in GAG modification on the biological properties of HSPGs (51, 61, 63) .
Cerebroglycan Expression Marks a Distinct Stage in Neuronal Development
Examination of patterns of cerebroglycan message expression by in situ hybridization suggests that cerebroglycan rnRNA (a) is produced by neurons, (b) appears at around the time of a neuron'g terminal mitosis, and (c) disappears by the time that neuronal migration and axonal extension have been completed.
Strong support for this interpretation comes from examination of the developing cerebellum, in which neuronal birth, migration and maturation occur in distinct anatomical layers (66) . In that structure, cells that proliferate in the superficial part of the external granule layer give rise to postmitotic neurons that reside in the deep part of the same layer, and these in turn migrate rapidly through the molecular layer to reach their final positions in the internal granule layer. The concentration of cerebroglycan mRNA in the deep half of the external granule layer (Fig. 8 A) implies that cerebroglycan begins to be expressed at or after final mitosis, while its absence from the internal granule layer implies that cerebroglycan message disappears by the time cell body migration has finished. From studies of the timing of cerebeUar neuron migration (26) , it can be concluded that the window of cerebroglycan mRNA expression in granule cells is "~36 h or less.
The view that cerebroglycan is first expressed when neurons become postmitotic is supported by results in the early spinal cord, in which mRNA is found only in regions containing newly generated neurons (Fig. 8 B) , and by the fact that all sites of cerebroglycan mRNA expression throughout the nervous system contain neurons that have been generated within the preceding 2- In contrast, little if any cerebroglycan mRNA is found in the proliferating neural precursors that form the ventricular zone, both in the El2 spinal cord (Fig. 8 B) and throughout the developing brain (not shown).
The time of disappearance of cerebroglycan message in at least one structure other than the cerebellum also correlates with completion of neuronal migration: cells expressing cerebroglycan are found in the subventricular zone pathway along which olfactory bulb interneuron precursors migrate (48), but not in the layers of the olfactory bulb that contain interneurons that have completed their migration. In other parts of the nervous system, however, a simple correlation between cerebroglycan expression and neuronal cell body migration cannot be drawn. The ventral horn of the spinal cord, the dorsal root ganglia, the El9 thalamus, the superficial layers of the El9 and P0 cerebral cortex, and the dentate gyrus of the hippocampus (Figs. 6-8 ), all primarily consist of neurons that have reached their final positions, yet express cerebroglycan. Interestingly, although the cell bodies of these neurons are not migrating at these times, their axons are generally still growing. If the same ceils are examined after their axons have reached target areas, cerebroglycan message is undetectable (e.g., after E20 for thalamus [22] ; El8 for dorsal root ganglia [38] ; and P2-P5 for cerebral cortex [52] ). Since axon growth and cell migration are both forms of cell motility (9, 18) , the data suggest a general correlation between cerebroglycan expression and periods of time during which neurons engage in motile behaviors.
Although the data presented cannot rule out the possibility that some glial cells transiently express cerebroglycan, neither the timing nor pattern of expression of cerebroglycan match the timing or sites of glial production in the brain, which is largely postnatal (34) . In addition, several of the structures in the developing brain that highly express cerebroglycan mRNA contain few if any glial cell bodies, e.g., the external granule layer of the cerebellum (Fig. 8) and the El8 retina (data not shown). Interestingly, recent evidence indicates that, in the adult rat brain, glypican is also expressed largely, if not exclusively, by neurons (46) .
Possible Roles for Cerebroglycan in the Developing Nervous System
If cerebroglycan is expressed by neurons specifically at times of cell migration and axon pathfinding, it raises the possibility that cerebroglycan plays a role in these events. Many of the molecules that have been implicated in the control of these cell behaviors-including extracellular matrix glycoproteins, polypcptide growth factors, and cell-cell adhesion molecules-share a common feature: they bind GAGs, especially HS and the related GAG heparin (42) . The abundance (30) and pattern of expression of cerebroglycan in the developing nervous system suggest that it could play an important role in the recognition of these classes of molecules.
For example, axons that leave the cerebral cortex navigate within a layer that contains both fibronectin (65) and laminin (32) , two extracellular matrix proteins that promote axon growth in vitro. Both of these proteins bind HSPGs, and recent studies suggest that cell surface HSPGs are essential for the interactions of central nervous system neurons with fibronectin (29) . Importantly, expression of cerebroglycan in the cerebral cortex occurs during the major period of cortical axon growth through this region (20) . Laminin is also present along pathways followed by retinal axons (15, 50) , as well as those followed by the peripheral axons of spinal motoneurons and dorsal root ganglion neurons (56) . In each case, we now know that these pathways are navigated by neurons that, at the time, express cerebroglycan mRNA. Moreover, if the cellular distribution of cerebroglycan is similar to that of other GPI-anchored proteins expressed by neurons, this HSPG is likely to be found on the surface of axons (e.g., 24, 27, 76) .
Other potential ligands for cerebroglycan in the developing nervous system include the cell adhesion molecule NCAM-which appears to require an interaction with HSPGs for at least some of its functions (16, 55)-and hepafin binding growth factors such as FGF-1, FGF-2, and FGF-5, which are known to influence neuronal survival and neurite outgrowth in vitro (31, 70, 73, 74) , and which apparently require HSPGs to interact with cells (54, 78).
The fact that cerebroglycan is a GPI-anchored molecule also raises the possibility that the binding of ligands to cerebroglycan could lead to the production of intraceUular signals. Crosslinking of any of a wide variety of GPIanchored proteins on the surface of leukocytes is known to trigger changes in intracellular calcium levels, protein secretion and cell proliferation (47, 53). The mechanism of GPImediated signal transduction has not been determined, but may involve the interaction of GPI-anchored proteins with transmembrane proteins such as tyrosine kinases (69), or the phospholipase-induced cleavage of the GPI-anchor, followed by rebinding of the anchor to a specific signal-transducing receptor (59). Future studies aimed at determining precisely which molecules cerebroglycan interacts with, and what the intracellular consequences of those interactions are, will be critical in defining the in vivo functions of this molecule.
